Diagnosis Terminology Affects Treatment Decisions

Published Online: Thursday, November 14, 2013
Follow Pharmacy_Times:
According to a recent study published online on August 26, 2013, in JAMA Internal Medicine, women diagnosed with ductal carcinoma in situ (DCIS), a noninvasive breast malignancy, may be more likely to choose surgery over noninvasive options when the condition is described using the word “cancer.”

Recognizing that many women are unable to distinguish between invasive and noninvasive cancers, especially with inconsistent terminology, the researchers investigated whether women’s treatment decisions would be affected by the words used to describe the diagnosis. The study enrolled 394 healthy women and presented them with 3 terms to describe a DCIS diagnosis: noninvasive breast cancer, breast lesion, and abnormal cells. Each term was accompanied by an identical table of risks and 3 treatment options, including surgery, medication, and active surveillance. Women viewed each term separately and were asked to make a treatment decision for each.

The results indicated that women changed their treatment decision when different terms were used to describe DCIS. When the condition was described as “noninvasive breast cancer,” 47% of women said they would want surgery. However, when DCIS was described as a “breast lesion,” 34% wanted surgery, and 31% selected surgery when “abnormal cells” was used.

The authors suggest that many women want nonsurgical treatment when they better understand the risks, but the word “cancer” may scare patients and prevent them from choosing less aggressive treatment.

Related Articles
Specialty pharmacy is often considered one of the fastest growing and least understood segments of health care.
Cancer treatment is more closely involving community and specialty pharmacies, as many patients are being treated with oral, subcutaneous, and intravenous (IV) agents in the comfort of their own homes.
As the summer months heat up, Rite Aid is proud to serve as the presenting sponsor of The Skin Cancer Foundation's annual Road to Healthy Skin Tour for the eighth consecutive year.
With the FDA’s approval of Gardasil 9, this vaccine will now be available as a preventive measure against up to 90% of genital, anal, vulvular, and vaginal cancers, thereby offering additional protection for pediatric patients from the human papillomavirus.
Latest Issues
$auto_registration$